Something to think about regarding Sanofi's long term intention regarding MannKind.
Here is the perfect example of where we will be heading with Sanofi. This deal occurred in January 2014.
Sanofi to Buy 12% of Alnylam, Expands Rare-Disease Drug Deal
The $700 million deal strengthens the development partnership of the two, while reinforcing Sanofi's commitment to rare disease
French drugmaker Sanofi will buy a 12 percent stake in Alnylam Pharmaceuticals Inc for $700 million and deepen their partnership to develop drugs for rare genetic diseases.
The companies said in a joint statement on Monday that Sanofi would buy Alnylam shares for about $80 each, representing a 27 percent premium compared to their average price over the past 30 days.
The partnership between Sanofi and Alnylam began in 2012, the year after Sanofi jumped into the business of treating rare genetic diseases by paying more than $20 billion for U.S. biotechnology company Genzyme, a leader in the field.
Share price January 3rd 2012. $8.33 per share
September 2012 partnership announced with Sanofi. $20.74
January 10, 2014 share price close of market $66.21 per share.
Announcement of a purchase of 12% interest in Alnylam by Sanofi prior to market open on January 13, 2014 market share price at open $85.36 per share and at market close 1/13/2014 $93.28 per share.
So today's MannKind share price at $6.10 per share could be just like Alnylam's. It took about 16 months after partnership for Sanofi to buy 12% of Alnylam. That now stands today at 13%.
WI'll Sanofi do the same with MannKind? A blockbuster type drug they can sell for many years in the USA and later in a 120 countries. I think we will have a winner if we just sit back for 12 to 18 months. I don't think it will take Sanofi 18 months to buy a 10% or more interest in MannKind. I predict this will happen before the end of 2014 now that the HSR approval is behind us.
